TRANSCURE-BIOSERVICES
TransCure bioServices (France), a one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, today announced that it has completed a 2.5 million euros funding with Financière Arbevel (France). This financing round will enable the company, healthy and profitable for the last three years, to accelerate its international sales growth as well as to expand in vivo preclinical pharmacology services offers into new product lines.
This financing was entirely subscribed by Arbevel Life Sciences Crossover I, a european private equity fund based in Paris (France) with a cross-over approach. TransCure bioServices will use the proceeds to expand its profitable business activities in Europe and the USA, and to develop additional platforms for international pharmaceutical and biotech companies.
Marc Le Bozec , Managing Director of Arbevel Life Sciences Crossover I Fund, will now join the Supervisory Board of the company and commented: “We are excited to collaborate with TransCure bioServices’ management in expediting its growth by addressing new markets and strengthening its commercial team”.
Patrick Nef , Chief Executive Officer and co-founder of TransCure bioServices, commented: “We welcome Arbevel as a new shareholder to boost our healthy and profitable international CRO business which generated significant growth over the past 3 years. In addition to the ongoing full human immune system mouse models for immuno-oncology, inflammation, and infectious diseases we are excited to develop new hu-liver and 100% human monoclonal antibody services. We look forward to the contribution of Marc Le Bozec in the Supervisory Committee and to benefit from his expertise of preclinical CRO business and financial markets.”
“Arbevel’s investment underlines a steppingstone for the growth of our worldwide business,” says Stéphane Legastelois , Chairman of TransCure bioServices. “It allows TransCure bioServices to widen its range of services and to investigate new exciting areas in the field of full human antibodies.”
Agile Capital Markets acted as financial advisor for TransCure bioServices in this transaction.
About TransCure bioServices SAS.
TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines. If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, contact us at www.tcbioservices.com
About Financière Arbevel
Founded in 1997, Financière Arbevel, an entrepreneurial investment management company, has grown significantly since its takeover by the current owners in early 2009 – the AUM progressed from EUR 25m to EUR 1.6bn as of today (of which EUR 732m under the umbrella SICAV “Pluvalca” comprising 9 sub-funds). The company currently employs a total of 34 staff, of which 13 are dedicated to fund management/investment research. Financière Arbevel is recognized for its expertise within the small & mid cap asset class. We are a research-driven organization with a strong emphasis on fundamental financial and strategic analysis, close relationships with top managements of listed companies (more than 1000 company meetings last year) and a permanent quest for new investment themes offering structural growth opportunities. The digitalization, fintech, Industry 4.0, or the ageing of the world population are some of our favorite investment themes. We ensure we 3/3 are following closely the latest developments within this universe, by participating in various conferences, trade fairs, sector-specific thematic events and by meeting regularly with managements of listed companies. Our small & mid cap DNA is spread across various strategies under the PLUVALCA family of funds with a cross-asset approach comprising our core equity funds, thematic equity funds, fixed income and diversified/flexible allocation funds). In 2015, the Norwegian sovereign wealth fund chose Financière Arbevel to manage its French equity mandate. In 2018, Financière Arbevel pursued its development by launching its first European private equity fund (FPCI form or “Professional private equity investment fund”) with a cross-over approach focused on the non-listed life-science universe, with the idea of accompanying a limited number of biotechnology start-ups in their development. www.arbevel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005005/en/
Contact:
TransCure bioServices SAS Patrick Nef, PhD Chief Executive Officer Email: info@tcbioservices.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Won't Transform Mobility Without Unprecedented Collaboration, Study Reveals8.12.2025 09:25:00 CET | Press release
First comprehensive analysis of real-world AI applications exposes critical gap between technology's promise and scaled deployment, according to the MIT Mobility Initiative and Kearney Advanced Mobility Institute Artificial intelligence is quietly reshaping global transportation systems, but most deployments remain isolated pilots that haven't achieved scale – and the gap between AI's promise and its execution is widening, according to a landmark study launched today at CoMotion GLOBAL in Riyadh. The Envisioning the Future of Mobility Powered by AI report, developed by the MIT Mobility Initiative and Kearney Advanced Mobility Institute, analyzed input from 55 leading global organizations, including Google, Lyft, Uber Freight, Deutsche Bahn, and NEOM. The study mapped real-world AI applications across mobility systems in Europe, the Americas, APAC, and the Middle East – revealing both breakthrough potential and fundamental challenges in bringing AI-powered mobility to scale. The report
ATEC2025·Real-World Extreme Challenge Concludes with Zhejiang University Team Claiming $150,000 Prize for Breakthrough in Fully Autonomous Robotics8.12.2025 09:25:00 CET | Press release
Thirteen global teams push the boundaries of “no remote control” robotics, driving the evolution from teleoperated tools to autonomous agents The ATEC2025·Real-World Extreme Challenge successfully concluded on December 7 on the campus of The Chinese University of Hong Kong. A team from Zhejiang University emerged victorious from a field of 13 talented international squads by demonstrating exceptional fully autonomous embodied intelligence, securing the top prize of $150,000 USD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207877880/en/ A Zhejiang University team wins ATEC2025·Real-World Extreme Challenge Organized by the Chinese University of Hong Kong and co-hosted by Advanced Technology Exploration Community (ATEC), Peking University, Beijing Normal University, and Ant Group, ATEC2025·Real-World Extreme Challenge was the world’s first intelligent robotics challenge held entirely outdoors on natural terrain—featuring
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom